Although BCR::ABL inhibitors have improved the prognosis of CML, relapse due to the regrowth of treatment-resistant CML stem cells remains a major clinical problem. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.